NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

25.40

+0.14

(+0.55%)

At close: 4:01 PM EDT

25.44

+0.04

(+0.16%)

After hours: 7:10 PM EDT

A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed

Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.

Investor's Business Daily 54 minutes ago

PFE
+0.55%
AMZN

AMD
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves

Benzinga 2 hours ago

PFE
+0.55%
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

Investor's Business Daily 3 hours ago

PFE
+0.55%
Sector Update: Health Care Stocks Edge Higher Late Afternoon

Sector Update: Health Care Stocks Edge Higher Late Afternoon

PREMIUM
MT Newswires 3 hours ago

PTCT

RMD

PFE
+0.55%
Pfizer Gets FDA Approval for Bleeding Disorder Treatment

Pfizer Gets FDA Approval for Bleeding Disorder Treatment

PREMIUM
MT Newswires 5 hours ago

PFE
+0.55%
Pfizer Receives FDA Approval for Bleeding Disorder Treatment

Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.

Barrons.com 8 hours ago

PFE
+0.55%
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks 9 hours ago

PFE
+0.55%
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 10 hours ago

ABBV

PFE
+0.55%
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

Motley Fool 11 hours ago

PFE
+0.55%
T
+1.03%
BNS
UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder

The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, which can cause spontaneous as well as severe bleeding following injuries or surgery.

Reuters 12 hours ago

PFE
+0.55%
Pfizer hemophilia gene therapy arrives in US to uncertain future

The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.

BioPharma Dive 12 hours ago

PFE
+0.55%
BMRN
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

NEW YORK, April 26, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var)

Business Wire 12 hours ago

PFE
+0.55%
Should You Buy Moderna Before May 12?

This ambitious biotech aims to launch 15 products over the coming five years.

Motley Fool 14 hours ago

MRNA

PFE
+0.55%
Wall Street plunges after US inflation shock

US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.

The Telegraph yesterday

^FTSE

PFE
+0.55%
BHP
Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

PREMIUM
MT Newswires yesterday

PFE
+0.55%
BNTX
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.

The Wall Street Journal yesterday

REGN

PFE
+0.55%
BMY
+0.34%
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters yesterday

PFE
+0.55%
GSK

BNTX
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters yesterday

GSK

PFE
+0.55%
BNTX
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth

British ad group WPP reported a 1.6% drop in organic growth in the first quarter, lagging its major rivals, after it was hit by loss of business from healthcare client Pfizer and reduced spending by technology companies. WPP, which had already warned that any organic growth this year would be weighted towards the second half, on Thursday reiterated its guidance for flat to 1% growth this year, with a margin improvement of 20-40 basis points.

Reuters yesterday

PFE
+0.55%
Pfizer Declares Second-Quarter 2024 Dividend

NEW YORK, April 24, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.

Business Wire 2 days ago

PFE
+0.55%

Performance Overview

Return	PFE	S&P 500
YTD	-10.45%	+6.92%
1-Year	-32.10%	+25.26%
3-Year	-26.01%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE)

A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Pfizer Gets FDA Approval for Bleeding Disorder Treatment

Pfizer Receives FDA Approval for Bleeding Disorder Treatment

Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics

AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder

Pfizer hemophilia gene therapy arrives in US to uncertain future

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

Should You Buy Moderna Before May 12?

Wall Street plunges after US inflation shock

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth

Pfizer Declares Second-Quarter 2024 Dividend

Performance Overview